Aquestive Therapeutics, Inc.
AQST
$5.39
$0.316.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -68.76% | 64.86% | -86.81% | -34.21% | -393.55% |
| Total Depreciation and Amortization | -2.86% | -18.71% | -8.24% | -12.58% | -31.71% |
| Total Amortization of Deferred Charges | -35.70% | -16.87% | 1.85% | 2.81% | 2.96% |
| Total Other Non-Cash Items | 700.27% | 98.41% | -44.01% | 71.15% | 49.02% |
| Change in Net Operating Assets | -437.43% | -148.16% | 262.13% | 40.44% | 110.99% |
| Cash from Operations | -19.29% | 36.73% | -30.51% | -6.47% | -12.96% |
| Capital Expenditure | -98.13% | 61.48% | -466.67% | -193.75% | -205.71% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -98.13% | 61.48% | -466.67% | -193.75% | -205.71% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -562,525.00% | -33.33% | 0.00% | 12.50% | -60.00% |
| Issuance of Common Stock | -- | -77.72% | 306.55% | 42,121.76% | -- |
| Repurchase of Common Stock | -3,668.60% | 53.20% | -1,700.00% | 65.35% | -1,620.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -155,850.00% | -- | 100.00% | -- | -- |
| Cash from Financing | -2,491.00% | -78.58% | 320.38% | 478,988.24% | -105.84% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -50.77% | -261.20% | -24.37% | 672.15% | -52.36% |